{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:32Z","timestamp":1789614152020,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104853","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:02:23Z","timestamp":1782802943000},"page":"104853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody\u2013drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-7594","authenticated-orcid":false,"given":"Mariana Carvalho","family":"Gouveia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-3609","authenticated-orcid":false,"given":"Pedro Jos\u00e9 Galv\u00e3o","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7727-307X","authenticated-orcid":false,"given":"Caio Guilherme Souza","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4378","authenticated-orcid":false,"given":"Caio Abner","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Migliavacca","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-922X","authenticated-orcid":false,"given":"Renata Colombo","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-0571","authenticated-orcid":false,"given":"Adriana","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-9876","authenticated-orcid":false,"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2026.104853_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"International consensus guidelines management advanced breast cancer (ABC 6 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104853_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clbc.2021.10.002","article-title":"Real-world outcomes everolimus exemestane after CDK4\/6 inhibitors metastatic HR+ breast cancer","volume":"22","author":"Mo","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104853_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/annonc\/mdz394.010","article-title":"KEYNOTE-119: phase III study pembrolizumab vs chemotherapy metastatic TNBC","volume":"30","author":"Cort\u00e9s","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104853_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf034","article-title":"Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States","volume":"30","author":"Punie","year":"2025","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib7","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104853_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking potential antibody-drug conjugates cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-021-00472-z","article-title":"Clinical development new antibody-drug conjugates breast cancer: infinity beyond","volume":"35","author":"Sousa","year":"2021","journal-title":"BioDrugs"},{"issue":"16","key":"10.1016\/j.breast.2026.104853_bib11","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"issue":"6","key":"10.1016\/j.breast.2026.104853_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing safety ADCs solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104853_bib14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"ADCs bystander killing: antigen-dependent internalization required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib15","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.breast.2026.104853_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.breast.2026.104853_bib17","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, novel HER2-Targeting ADC novel DNA topoisomerase I inhibitor, demonstrates promising antitumor efficacy differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104853_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/membranes11030199","article-title":"Trastuzumab modulates protein cargo extracellular vesicles released ERBB2+ breast cancer cells","volume":"11","author":"Marconi","year":"2021","journal-title":"Membranes"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib19","first-page":"1","article-title":"Latest research development antibody-drug conjugate, sacituzumab govitecan","author":"Nakada","year":"2019","journal-title":"Expert Opin Invest Drugs"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2026.104853_bib21","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity efficient drug delivery tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib22","first-page":"2486","article-title":"Safety preliminary activity datopotamab deruxtecan, TROP2-directed antibody-drug conjugate, patients advanced solid tumors: results from phase 1 study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.breast.2026.104853_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: novel antibody drug conjugate triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.breast.2026.104853_bib24","article-title":"Preclinical profiles SKB264, novel anti-TROP2 antibody conjugated topoisomerase inhibitor, demonstrated promising antitumor efficacy compared IMMU-132 [published correction appears front oncol","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104853_bib25","first-page":"1022","article-title":"Preclinical characterization SKB264, novel anti-TROP2 antibody-drug conjugate, TROP2-expressing solid tumors","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104853_bib44","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/fon-2023-0188","article-title":"TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2- breast cancer","volume":"20","author":"Bardia","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib46","first-page":"S1566","volume":"36","author":"Dent","year":"2025","journal-title":"ESMO"},{"key":"10.1016\/j.breast.2026.104853_bib47","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival sacituzumab govitecan hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.breast.2026.104853_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104853_bib49","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan HR+HER2- metastatic breast cancer: randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104853_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104853_bib51","doi-asserted-by":"crossref","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro previously untreated PD-L1-positive advanced triple-negative breast cancer (TNBC): primary results from randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib41","first-page":"1","article-title":"Sacituzumab tirumotecan previously treated metastatic triple-negative breast cancer: randomized phase 3 trial","author":"Yin","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104853_bib42","first-page":"S1683","volume":"36","author":"Fan","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104853_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile trastuzumab deruxtecan advanced breast cancer: expert opinion adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management trastuzumab deruxtecan clinical practice breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104853_bib28","series-title":"NCCN clinical practice guidelines oncology (NCCN Guidelines\u00ae): Antiemesis. Version 2.2025","year":"2025"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","volume":"36","author":"Rugo","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2025.43.16_suppl.1015","article-title":"Treatment rechallenge after trastuzumab-deruxtecan\u2013related interstitial lung disease: a multi-institution cohort study","volume":"43","author":"Natsuhara","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-025-01967-1","article-title":"Evaluating risk factors for trastuzumab-deruxtecan pneumonitis in patients with metastatic breast cancer","volume":"27","author":"Henricks","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105847","article-title":"Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer","volume":"10","author":"Antonarelli","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104853_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-026-00936-x","article-title":"Comparison of T-DXd-Associated pulmonary toxicity in real-world settings and clinical trials","author":"Udovica","year":"2026","journal-title":"NPJ Breast Cancer"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib35","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1200\/JCO.2025.43.16_suppl.12125","article-title":"Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates","volume":"43","author":"Yekeduz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/14712598.2023.2267975","article-title":"Managing adverse events sacituzumab govitecan","volume":"23","author":"Schlam","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.breast.2026.104853_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105308","article-title":"Effectiveness sacituzumab govitecan management neutropenia patients metastatic triple-negative breast cancer treated real-world settings United States","volume":"10","author":"Nanda","year":"2025","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib38","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","article-title":"Prevention sacituzumab govitecan (SG)-related neutropenia diarrhea patients (pts) triple-negative HR+\/HER2- advanced breast cancer (ABC; PRIMED): phase 2 trial","volume":"42","author":"P\u00e9rez Garc\u00eda","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.70060","article-title":"UGT1A1 and Sacituzumab Govitecan toxicity: a systematic review and meta-analysis","volume":"119","author":"Dello","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.breast.2026.104853_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, prophylaxis adverse events special interest associated datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104853_bib52","first-page":"B1","article-title":"Abstract LB1-04: efficacy safety trastuzumab deruxtecan (T-DXd) vs physician's choice chemotherapy (TPC) pace disease progression prior endocrine-based therapy: additional analysis from DESTINY-Breast06","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104853_bib53","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5_Supplement","key":"10.1016\/j.breast.2026.104853_bib54","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1158\/1538-7445.SABCS22-GS1-11","article-title":"Abstract GS1-11: Sacituzumab Govitecan (SG) vs treatment Physician's choice (TPC): efficacy Trop-2 expression TROPiCS-02 study patients (pts) HR+\/HER2- metastatic breast cancer (mBC)","volume":"83","author":"Rugo","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104853_bib55","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1016\/j.annonc.2022.07.253","article-title":"214MO Sacituzumab govitecan (SG) efficacy hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2-) metastatic breast cancer (MBC) HER2 immunohistochemistry (IHC) status phase III TROPiCS-02 study","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104853_bib56","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1004","article-title":"SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer","volume":"42","author":"Garrido-Castro","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib57","series-title":"Presented at: san antonio breast cancer symposium (SABCS)","article-title":"Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2- (IHC 0, 1+, 2+\/ISH-) metastatic breast cancer: primary results from ASCENT-07","author":"Jhaveri","year":"2025"},{"issue":"3","key":"10.1016\/j.breast.2026.104853_bib58","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annonc.2025.01.009","article-title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): final overall survival (OS) from the phase III TROPION-Breast01 trial","volume":"36","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104853_bib59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104853_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1000","volume":"44","author":"Kalinsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib61","series-title":"LBA 22- patient-reported outcomes with Sacituzumab Govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer in the phase 3 ASCENT-04\/KEYNOTE-D19 study","author":"Azambuja","year":"2025"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib62","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2026.44.16_suppl.1001","volume":"44","author":"Hurvitz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib63","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.2025.43.16_suppl.1019","article-title":"Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from the phase II OptiTROP-Breast05 study","volume":"43","author":"Yin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104853_bib64","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib65","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/j.annonc.2025.08.978","article-title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): final results from the phase Ib\/II BEGONIA study","volume":"36","author":"Schmid","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","author":"Dent","year":"2026","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib67","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2026.44.16_suppl.1002","volume":"44","author":"Cescon","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104853_bib68","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity safety trastuzumab deruxtecan patients HER2-Low-Expressing advanced breast cancer: results from phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104853_bib69","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-02-02","article-title":"Abstract P1-02-02: indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): safety and efficacy analysis","volume":"31","author":"Pathak","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) definition, diagnosis, management HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104853_bib71","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P3-09-20","article-title":"Abstract P3-09-20: re-evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 0 or 1+ in metastatic breast cancer (mBC) samples to characterize the proportion of HER2-ultralow (IHC 0 with membrane staining)","volume":"31","author":"Krishnamurthy","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104853_bib72","doi-asserted-by":"crossref","first-page":"S1213","DOI":"10.1016\/j.annonc.2024.08.2259","article-title":"LBA21 human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor\u2013positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)","volume":"35","author":"Salgado","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-025-00741-y","article-title":"Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies","volume":"11","author":"Bar","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100009","article-title":"Interobserver variation in the assessment of immunohistochemistry expression levels in HER2-Negative breast cancer: can we improve the identification of low levels of HER2 expression by adjusting the criteria? An international interobserver study","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ajcp\/aqaf043","article-title":"Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: reasons for discordance and impact of a single training session","volume":"164","author":"Tseng","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"22","key":"10.1016\/j.breast.2026.104853_bib76","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib77","article-title":"Fully automated artificial intelligence solution for human epidermal growth factor receptor 2 immunohistochemistry scoring in breast cancer: a multireader study","volume":"8","author":"Krishnamurthy","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100944","article-title":"Agreement across 10 artificial intelligence models in assessing human epidermal growth factor receptor 2 (HER2) expression in breast cancer whole-slide images","volume":"39","author":"McKelvey","year":"2026","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.breast.2026.104853_bib79","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104853_bib80","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody\u2013drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104853_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist Updates"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib82","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody\u2013drug conjugate therapy in breast cancer","volume":"32","author":"Rampa","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104853_bib83","first-page":"0","article-title":"Re-evaluating antibody\u2013drug conjugate linker stability: assessment, interpretation, and clinical translation","author":"Colombo","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104853_bib84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy administration sequence: Sacituzumab Govitecan Trastuzumab Deruxtecan HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104853_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes trastuzumab deruxtecan biomarker status, line treatment prior receipt sacituzumab govitecan large real-world database patients metastatic breast cancer","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104853_bib86","article-title":"Sequencing antibody\u2013drug conjugates in metastatic breast cancer: a systematic review","volume":"142","author":"de Almeida","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib87","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib88","article-title":"Mechanisms of resistance to Trastuzumab Deruxtecan in breast cancer elucidated by multi-omic molecular profiling","volume":"12","author":"Gw","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104853_bib89","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jnci\/djaf344","article-title":"Molecular and clinical insights of Trastuzumab Deruxtecan efficacy in advanced breast cancer","volume":"118","author":"Nassar","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.breast.2026.104853_bib90","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104853_bib91","article-title":"Quantitative multiplex immunofluorescence assay for trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2 expression in breast cancer: toward guiding patient selection for antibody-drug conjugate therapies","volume":"9","author":"Robbins","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104853_bib92","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2024.42.16_suppl.3140","article-title":"Evaluation of a predictive biomarker for antibody drug conjugates (ADCs)","volume":"42","author":"Thomas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104853_bib93","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104853_bib94","article-title":"Trastuzumab deruxtecan patients previously treated HER2-low advanced breast cancer active brain metastases: DEBBRAH trial","volume":"9","author":"Batista","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib95","article-title":"The DEBBRAH trial: trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"M\u00e9d Sur"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00736-9","article-title":"Real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases","volume":"11","author":"Grinda","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.breast.2026.104853_bib97","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Bartsch","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104853_bib98","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104853_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104090","article-title":"Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2","volume":"190","author":"Schlam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.breast.2026.104853_bib100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a First-in-Human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104853_bib101","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","article-title":"Recent advances in bispecific antibody-drug conjugates for breast cancer therapy","volume":"96","author":"Ji","year":"2026","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.breast.2026.104853_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104599","article-title":"Next-generation drug conjugates for breast cancer: clinical prospects and mechanism-based strategies to overcome resistance","volume":"31","author":"Zhao","year":"2026","journal-title":"Drug Discov Today"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:27:09Z","timestamp":1789612029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":102,"alternative-id":["S0960977626001633"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104853","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody\u2013drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104853"}}